These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 10569498)

  • 21. Vaccines based on recombinant antigen strategies.
    Minor P
    Dev Biol (Basel); 2001; 105():189-94. PubMed ID: 11763327
    [No Abstract]   [Full Text] [Related]  

  • 22. World wide experience with inactivated poliovirus vaccine.
    Bonnet MC; Dutta A
    Vaccine; 2008 Sep; 26(39):4978-83. PubMed ID: 18680777
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Re: world wide experience with inactivated poliovirus vaccine.
    Arya SC; Agarwal N
    Vaccine; 2009 Jan; 27(1):1. PubMed ID: 18952133
    [No Abstract]   [Full Text] [Related]  

  • 24. What role for inactivated poliovirus vaccine in the eradication endgame?
    Kew O
    J Infect Dis; 2006 May; 193(10):1341-3. PubMed ID: 16619179
    [No Abstract]   [Full Text] [Related]  

  • 25. Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, and haemophilus B conjugate vaccine and guidance for use in infants and children.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2008 Oct; 57(39):1079-80. PubMed ID: 18830213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anomalous observations on IPV and OPV vaccination.
    John TJ
    Dev Biol (Basel); 2001; 105():197-208. PubMed ID: 11763328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. When can we stop using oral poliovirus vaccine?
    Hull HF; Minor PD
    J Infect Dis; 2005 Dec; 192(12):2033-5. PubMed ID: 16288363
    [No Abstract]   [Full Text] [Related]  

  • 28. Inactivated vaccines based on alternatives to wild-type seed virus.
    Chumakov K; Dragunsky E; Ivshina A; Enterline J; Wells V; Nomura T; Gromeier M; Wimmer E
    Dev Biol (Basel); 2001; 105():171-7. PubMed ID: 11763325
    [No Abstract]   [Full Text] [Related]  

  • 29. A case of conjunctivitis associated with oral poliovirus type 2 vaccine (OPV).
    Jenkins R; Chiew YF; Langford D; Johns P; Huang S; Miller N
    Pathology; 2004 Oct; 36(5):505-6. PubMed ID: 15370124
    [No Abstract]   [Full Text] [Related]  

  • 30. A developing country perspective on vaccine-associated paralytic poliomyelitis.
    John TJ
    Bull World Health Organ; 2004 Jan; 82(1):53-7; discussion 57-8. PubMed ID: 15106301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization.
    Zangwill KM; Eriksen E; Lee M; Lee J; Marcy SM; Friedland LR; Weston W; Howe B; Ward JI
    Pediatrics; 2008 Dec; 122(6):e1179-85. PubMed ID: 19047220
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of injectable and oral polio vaccines in polio eradication.
    John J
    Expert Rev Vaccines; 2009 Jan; 8(1):5-8. PubMed ID: 19093765
    [No Abstract]   [Full Text] [Related]  

  • 33. Strengths and weaknesses of current polio vaccines--a view from industry.
    André FE
    Dev Biol (Basel); 2001; 105():61-6. PubMed ID: 11763338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inactivated Polio Vaccine (IPV): a strong candidate vaccine for achieving global polio eradication program.
    Shahzad A; Köhler G
    Vaccine; 2009 Aug; 27(39):5293-4. PubMed ID: 19638271
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy.
    Dragunsky EM; Ivanov AP; Wells VR; Ivshina AV; Rezapkin GV; Abe S; Potapova SG; Enterline JC; Hashizume S; Chumakov KM
    J Infect Dis; 2004 Oct; 190(8):1404-12. PubMed ID: 15378432
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Time for a worldwide shift from oral polio vaccine to inactivated polio vaccine.
    Shahzad A
    Clin Infect Dis; 2009 Oct; 49(8):1287-8. PubMed ID: 19780666
    [No Abstract]   [Full Text] [Related]  

  • 37. Routine vaccines across the life span, 2003.
    Zimmerman RK; Middleton DB; Burns IT; Clover RD
    J Fam Pract; 2003 Jan; 52(1 Suppl):S1-21. PubMed ID: 12556275
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polio eradication strategies in Indian recommendations under IAP Action Plan 2006.
    Shah NK; John TJ; Thacker N; Vashishtha V; Kalra A; Ugra D
    Indian Pediatr; 2006 Dec; 43(12):1057-63. PubMed ID: 17202602
    [No Abstract]   [Full Text] [Related]  

  • 39. Intestinal immunity following a combined enhanced inactivated polio vaccine/oral polio vaccine programme in Israel.
    Swartz TA; Green MS; Handscher R; Sofer D; Cohen-Dar M; Shohat T; Habib S; Barak E; Dror Z; Somekh E; Peled-Leviathan T; Yulzari R; Libling A; Mendelson E; Shulman LM
    Vaccine; 2008 Feb; 26(8):1083-90. PubMed ID: 18241962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 1,25-dihydroxyvitamin d3 enhances systemic and mucosal immune responses to inactivated poliovirus vaccine in mice.
    Ivanov AP; Dragunsky EM; Chumakov KM
    J Infect Dis; 2006 Feb; 193(4):598-600. PubMed ID: 16425140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.